*Investigators in the Costa Rica HPV Vaccine Trial (CVT) Group*

Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica—Bernal Cortés (specimen and repository manager), Paula González (LTFU: co-principal investigator), Rolando Herrero (CVT: co-principal investigator), Silvia E. Jiménez (trial coordinator), Carolina Porras (co-investigator), Ana Cecilia Rodríguez (co-investigator).

United States National Cancer Institute, Bethesda, MD, USA—Allan Hildesheim (co-principal investigator & NCI co-project officer), Aimée R. Kreimer (LTFU: co-principal investigator & NCI co-project officer), Douglas R. Lowy (HPV virologist), Mark Schiffman (CVT: medical monitor & NCI co-project officer), John T. Schiller (HPV virologist), Mark Sherman (CVT: QC pathologist), Sholom Wacholder (statistician).

Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA (HPV Immunology Laboratory)—Ligia A. Pinto, Troy J. Kemp

Georgetown University, Washington, DC, USA—Mary K. Sidawy (CVT: histopathologist)

DDL Diagnostic Laboratory, Netherlands (HPV DNA Testing)—Wim Quint, Leen-Jan van Doorn, Linda Struijk.

University of California, San Francisco, CA, USA- Joel M. Palefsky, Teresa M. Darragh

University of Virginia, Charlottesville, VA, USA- Mark H. Stoler

*Funding*

The Costa Rica HPV Vaccine Trial is a long-standing collaboration between investigators in Costa Rica and the NCI. The trial is sponsored and funded by the NCI (contract N01-CP-11005), with funding support from the National Institutes of Health Office of Research on Women's Health. GlaxoSmithKline Biologicals (GSK) provided vaccine and support for aspects of the trial associated with regulatory submission needs of the company under a Clinical Trials Agreement (FDA BB-IND 7920) during the four-year, randomized blinded phase of our study. John T. Schiller and Douglas R. Lowy report that they are named inventors on US Government-owned HPV vaccine patents that are licensed to GlaxoSmithKline and Merck and for which the National Cancer Institute receives licensing fees. They are entitled to limited royalties as specified by federal law. The other authors declare that they have no conflicts of interest. The NCI and Costa Rica investigators are responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation of the manuscript. Registered with Clinicaltrials.gov NCT00128661

Notes

We extend a special thanks to the women of Guanacaste and Puntarenas, Costa Rica, who gave of themselves in participating in this effort. In Costa Rica, we acknowledge the tremendous effort and dedication of the staff involved in this project; we would like to specifically acknowledge the meaningful contributions by Loreto Carvajal, Rebeca Ocampo, Cristian Montero, Diego Guillen, Jorge Morales and Mario Alfaro. In the United States, we extend our appreciation to the team from Information Management Services (IMS) responsible for the development and maintenance of the data system used in the trial and who serve as the data management center for this effort, especially Jean Cyr, Julie Buckland, John Schussler, and Brian Befano. We thank Dr. Diane Solomon (CVT: medical monitor & QC pathologist) for her invaluable contributions during the randomized blinded phase of the trial and the design of the LTFU and Nora Macklin (CVT) and Kate Torres (LTFU) for the expertise in coordinating the study. We thank the members of the Data and Safety Monitoring Board charged with protecting the safety and interest of participants during the randomized, blinded phase of our study (Steve Self, Chair, Adriana Benavides, Luis Diego Calzada, Ruth Karron, Ritu Nayar, and Nancy Roach) and members of the external Scientific HPV Working Group who have contributed to the success of our efforts over the years (Joanna Cain, Chair, Diane Davey, David DeMets, Francisco Fuster, Ann Gershon, Elizabeth Holly, Silvia Lara, Henriette Raventós, Wasima Rida, Luis Rosero-Bixby, Kristen Suthers, Amber D’Souza, Richard Roden and Peter Gilbert).

This trial is sponsored and funded by the NCI (contract N01-CP-11005), with funding support from the NIH Ofﬁce of Research on Women’s Health. GSK Biologicals SA provided vaccine and support for aspects of the trial associated with regulatory submission needs of the company under a US Food and Drug Administration (FDA) clinical trials agreement (FDA BB-IND 7920) during the 4-year, randomized, blinded phase of our study. Vaccine was provided for our trial by GSK Vaccines under a clinical trials agreement with the NCI. GSK Vaccines also provided support for aspects of the trial associated with regulatory submission needs of the company. The authors received no ﬁnancial support or other form of compensation related to the development of the manuscript. The trial is registered with clinicaltrials.gov (NCT00128661). The protocol is available at <http://proyectoguanacaste.org>.

We thank the staff in Costa Rica for their tremendous effort and dedication to this project; the US team from information management services for the development and maintenance of the data system used in the trial; Jean Cyr, Julie Buckland, and Brian Befano for their invaluable contributions; the members of the data and safety monitoring board for protecting the safety and interest of participants in our trial (Drs. Steve Self, Adriana Benavides, Luis Diego Calzada, Ruth Karron, and Ritu Nayar, as well as Nancy Roach); and members of the external scientiﬁc HPV working group who have contributed to the success of our efforts over the years (Drs. Joanna Cain, Diane Davey, David DeMets, Francisco Fuster, Ann Gershon, Elizabeth Holly, Henriette Raventós, Wasima Rida, Luis Rosero-Bixby, and Kristen Suthers, as well as Silvia Lara and Sarah Thomas). Investigators in the Costa Rica Vaccine Trial group include the following: Mario Alfaro, Manuel Barrantes, M. Concepción Bratti, Fernando Cárdenas, Bernal Cortés, Albert Espinoza, Yenory Estrada, Paula González, Diego Guillén, Roland Herrero, Silvia E. Jiménez, Jorge Morales, Luis Villegas, Lidia Ana Morera, Elmer Pérez, Carolina Porras, Ana Cecilia Rodríguez, Libia Rivas (Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, CostaRica);Enrique Freer, José Bonilla, Alfanso García-Piñeres, Sandra Silva, Ivannia Atmella, Margarita Ramírez (University of Costa Rica, San José, Costa Rica); Allan Hildesheim, Aimée R. Kreimer, Douglas R. Lowy, Nora Macklin, Mark Schiffman, John T. Schiller, Mark Sherman, Diane Solomon, Sholom Wacholder (NCI, Bethesda, Maryland ); Ligia Pinto, Troy Kemp (SAIC, NCI-Frederick, Frederick, Maryland); Claire Eklund, Martha Hutchinson (Women’s and Infants’ Hospital, Providence, Rhode Island); Mary Sidawy (Georgetown University , Washington, DC; and Wim Quint and Leen-Jan van Doorn (DDL Diagnostic Laboratory, Rijswijk, the Netherlands).

Conﬂict of interest: The NCI and Costa Rica investigators are responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation of the manuscript. GSK Biologicals was provided the opportunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for the ﬁnal content and interpretation.